Quidel Corporation

Summary

Profile

Financials

Events

Ownership

Options

Company Info

Industry	Medical Specialties
Sector	Health Technology
Employees	1,370
CEO	Mr. Douglas C. Bryant

Address	9975 Summers Ridge Road , San Diego, CA 92121
Phone	1.858.552.1100
Website	www.quidel.com

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.

Competitors

Company Name	3 Month %Change	1 Year %Change
Quidel Corp.	4.27%	-26.39%
NovoCure Ltd.	-33.81%	-35.37%
Teva Pharmaceutical Industries Ltd.	-15.08%	-19.34%
Penumbra, Inc.	-10.47%	10.03%
United Therapeutics Corp.	-11.77%	43.14%

Statement Summary

as of 4:00 ET PM 12/02/2021

Total Assets (MRQ)	2.1 B
Total Liabilities (MRQ)	472.3 M
Shareholders’ Equity (MRQ)	1.6 B
Total Revenue (Annual)	509.7 M
Net Income (Annual)	215.8 M

Earnings And Estimates

as of 4:00 ET PM 12/02/2021

Current Qtr EPS Estimate	4.74
Current FY EPS Estimate	15.25
Long Term EPS Growth Estimate	-27.00
Next Expected Earnings Date	//

QDEL vs S&P 500

as of 12/02/2021

	Relative To S&P 500	QDEL
4 Weeks	n/a	n/a
12 Weeks	n/a	n/a
YTD	n/a	n/a

Earnings Surprises

as of 4:00 ET PM 12/02/2021

Fiscal Quarter	Estimate	Actual	Surprise
09/2021	3.52	5.36	+52.10%
06/2021	1.20	0.75	-37.67%
03/2021	4.50	4.09	-9.01%
12/2020	9.94	10.78	+8.49%
09/2020	4.62	5.33	+15.37%
06/2020	0.95	1.55	+63.09%
03/2020	0.75	0.93	+23.45%
12/2019	0.61	0.71	+16.39%

Financial Strength

as of 4:00 ET PM 12/02/2021

Pre-Tax Margin	55.22
Net Margin	-13.25
Operating Margin	55.29
Return On Equity	71.12
Return On Assets	52.63
Inventory Turnover (TTM)	2.93
Sales Growth (MRQ)	53.32

Ratios

as of 4:00 PM ET 12/02/2021

Price/Earnings (TTM)	7.18
Price/Book (MRQ)	3.77
Price/Cash Flow (TTM)	6.80
Book Value (MRQ)	39.21
Quick Ratio (MRQ)	3.20
Current Ratio (MRQ)	3.87
Total Debt/Equity (MRQ)	0.09

Short Interest

as of 4:00 PM ET 12/03/2021

	% Short - 0.00%
	% Remaining Float - 100.00%

	Current	Last Month
Short Interest Date	n/a	n/a
Short Interest Shares	0	0
Short Interest Ratio	0.0	0.0

M Y M Y

Total Assets 0,0.00 0,0.00

Total Liabilities 0,0.00 0,0.00

Total Equity 0,0.00 0,0.00

M Y M Y

Total Revenue 0,0.00 0,0.00

EBT Exc.
Unusual Items 0,0.00 0,0.00

Net Income 0,0.00 0,0.00

M Y M Y

Cash from
Operations 0,0.00 0,0.00

Cash from
Activities 0,0.00 0,0.00

Cash from
Fin. Activities 0,0.00 0,0.00

Select Period

TOTAL ASSETS	TOTAL LIABILITIES	TOTAL EQUITY

Balance Sheet

	M Y
ASSETS
Cash And Equivalents	0,0.00
Receivables	0,0.00
Inventories	0,0.00
Other Current Assets	0,0.00
Total Current Assets	0,0.00
Property, Plant & Equipment, Gross	0,0.00
Accumulated Depreciation & Depletion	0,0.00
Property, Plant & Equipment, Net	0,0.00
Intangibles	0,0.00
Other Non-Current Assets	0,0.00
Total Non-Current Assets	0,0.00
TOTAL ASSETS	0,0.00
Liabilities & Shareholder Equity
Accounts Payable	0,0.00
Short Term Debt	0,0.00
Total Current Liabilities	0,0.00
Long Term Debt	0,0.00
Deferred Income Taxes	0,0.00
Other Non-Current Liabilities	0,0.00
Minority Interest	0,0.00
Total Non-Current Liabilities	0,0.00
Preferred Stock Equity	0,0.00
Common Stock Equity	0,0.00
Common Par	0,0.00
Additional Paid In Capital	0,0.00
Cumulative Translation Adjustment	0,0.00
Retained Earnings	0,0.00
Treasury Stock	0,0.00
Other Equity Adjustments	0,0.00
Total Capitalization	0,0.00
TOTAL EQUITY	0,0.00
TOTAL LIABILITIES & STOCK EQUITY	0,0.00
Total Common Shares Outstanding	0,0.00
Preferred Shares	0,0.00
Treasury Shares	0,0.00
Basic Weighted Shares Outstanding	0,0.00
Diluted Weighted Shares Outstanding	0,0.00
Number Of Employees	0,0.00
Number Of Part-Time Employees	0,0.00

Select Period

TOTAL REVENUES	EBT Excluding Unusual Items	NET INCOME

Income Statement

	M Y
Sales	0,0.00
Cost Of Sales	0,0.00
Gross Operating Profit	0,0.00
Selling, General, And Administrative Expenses	0,0.00
Research & Development	0,0.00
Operating Income Before D & A (EBITDA)	0,0.00
Depreciation & Amortization	0,0.00
Interest Income	0,0.00
Other Income - Net	0,0.00
Special Income / Charges	0,0.00
Total Income Before Interest Expenses (EBIT)	0,0.00
Interest Expense	0,0.00
Pre-Tax Income	0,0.00
Income Taxes	0,0.00
Minority Interest	0,0.00
Net Income From Continuing Operations	0,0.00
Net Income From Discontinued Operations	0,0.00
Net Income From Total Operations	0,0.00
Extraordinary Income/Losses	0,0.00
Income From Cum. Effect Of Acct. Change	0,0.00
Income From Tax Loss Carryforward	0,0.00
Other Gains / Losses	0,0.00
Total Net Income	0,0.00
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Preferred Dividends	0,0.00
Net Income Available To Common	0,0.00
Basic EPS From Continuing Ops.	0,0.00
Basic EPS From Discontinued Ops.	0,0.00
Basic EPS From Total Operations	0,0.00
Basic EPS From Extraordinary Inc.	0,0.00
Basic EPS From Cum Effect Of Accounting Change	0,0.00
Basic EPS From Tax Loss Carryf'd.	0,0.00
Basic EPS From Other Gains (Losses)	0,0.00
Basic EPS, Total	0,0.00
Basic Normalized Net Income/Share	0,0.00
EPS From Continuing Ops.	0,0.00
EPS From Discontinued Ops	0,0.00
EPS From Total Ops.	0,0.00
EPS From Extraord. Inc.	0,0.00
EPS From Cum Effect of Accounting Change	0,0.00
EPS From Tax Loss Carfd.	0,0.00
EPS From Other Gains (L)	0,0.00
EPS, Total	0,0.00
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Dividends Paid Per Share	0,0.00

Select Period

CASH FROM OPERATIONS	CASH FROM INVESTING ACTIVITIES	CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

	M Y
Cash Flow From Operating Activities
Net Income (Loss)	0,0.00
Operating Gains/Losses	0,0.00
Gross Operating Profit	0,0.00
(Increase) Decrease In Receivables	0,0.00
(Increase) Decrease In Inventories	0,0.00
(Increase) Decrease In Other Current Assets	0,0.00
(Decrease) Increase In Other Current Liabilities	0,0.00
(Increase) Decrease In Other Working Capital	0,0.00
Other Non-Cash Items	0,0.00
Net Cash From Continuing Operations	0,0.00
Net Cash From Discontinued Operations	0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities	0,0.00
Sale Of Property, Plant & Equipment	0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments	0,0.00
Purchases Of Property, Plant & Equipment	0,0.00
Acquisitions	0,0.00
Purchases Of Short-Term Investments	0,0.00
Other Cash From Investing Activities	0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities	0,0.00
Issuance Of Debt	0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock	0,0.00
Repayment Of Long-Term Debt	0,0.00
Repurchase Of Capital Stock	0,0.00
Payment Of Cash Dividends	0,0.00
Other Financing Charges, Net	0,0.00
Net Cash From Financing Activities	0,0.00
Effect Of Exchange Rate Changes	0,0.00
Net Change In Cash & Cash Equivalents	0,0.00

Earnings Estimates

as of 4:00 ET PM 12/02/2021

	Current Qtr (12/2021)	Next Qtr (03/2022)
Consensus Estimate	$4.74	$2.53
# of Estimates	5	5
High Estimate	$5.60	$3.50
Low Estimate	$3.98	$2.00
Year Ago EPS	$11.14	$4.19
Year Over Year Growth Estimate	-57.42%	-39.70%

	Current Yr (12/2021)	Next Yr (12/2022)
Consensus Estimate	$15.25	$7.10
# of Estimates	5	5
High Estimate	$16.10	$10.11
Low Estimate	$14.50	$5.25
Year Ago EPS	$18.60	$15.25
Year Over Year Growth Estimate	-18.00%	-53.47%

	Current Qtr (12/2021)	Next Qtr (03/2022)	Current Year (12/2021)	Next Year (12/2022)
Consensus Estimate	$4.74	$2.53	$15.25	$7.10
# of Estimates	5	5	5	5
High Estimate	$5.60	$3.50	$16.10	$10.11
Low Estimate	$3.98	$2.00	$14.50	$5.25
Year Ago EPS	$11.14	$4.19	$18.60	$15.25
Year Over Year Growth Estimate	-57.42%	-39.70%	-18.00%	-53.47%

Insider Information Summary

as of 11/30/2021

	% Insiders - 12.00%
	% Remaining Total Shares - 88.00%

	Current	1 Month
Net Insider Transaction	2.41 K	2.37 K
Shares Bought	4.38 K	4.26 K
Shares Sold	1.97 K	1.89 K

Insider Activity

Purchases

Sales

Options Exercised

Options Awarded

Transaction Date	Insider/Title	Transaction Type	Market Value	Shares	Average Price	Current Holdings

Learn to Trade Like a Pro

Master The Market with the Help of Our Financial Experts

SUBSCRIBE NOW

INVESTING

CCXI PLUG QDEL

By Rob Lenihan

Oct 8, 2021 4:18 PM EDT

Latest News

May 4, 2021 8:43 AM EDT

May 3, 2021 2:41 PM EDT

Honeywell Is Sitting on a Massive Cash Pile Just Waiting to Be Spent

Apr 26, 2021 9:28 AM EDT

Apr 26, 2021 9:20 AM EDT

Apr 23, 2021 12:22 PM EDT

More than 210 Chinese firms with a combined market capitalisation of about US$2.2 trillion were listed on major US stock exchanges as of October. Photo: AFP

Apr 15, 2021 6:53 PM EDT

Apr 1, 2021 12:55 PM EDT

Dollar General Reports Earnings on Thursday - Here's What Jim Cramer Expects

Feb 22, 2021 8:55 PM EST

Feb 22, 2021 6:53 PM EST

Xpeng's US$1.98 Billion Credit Line From State-owned Banks Suggests China Is Throwing Weight Behind Leading Electric Vehicle Firms

Feb 22, 2021 8:51 AM EST

Nov 9, 2020 12:40 PM EST

Nov 5, 2020 6:54 PM EST

Oct 28, 2020 7:00 PM EDT

New York Stock Exchange is one of several US exchanges that has been flooded with Chinese cash in the past year. Photo: AFP

Oct 13, 2020 7:10 PM EDT

Jul 17, 2020 4:23 PM EDT

Jun 17, 2020 7:11 PM EDT

May 15, 2020 11:48 AM EDT

May 11, 2020 10:28 AM EDT

FTC Approves Abbott's Acquisition of Alere, Stock Jumps

Jul 20, 2017 12:00 PM EDT

Jul 19, 2017 3:56 PM EDT

FTSE Outpaces S&P 500 For Boardroom Gender Diversity

Jul 18, 2017 5:21 PM EDT

New Lifetime High Reached By WGL Holdings (WGL)

Aug 4, 2016 1:00 PM EDT

Trade-Ideas: Marvell Technology Group (MRVL) Is Today's Post-Market Leader Stock

Jan 14, 2016 10:04 AM EST

Oct 30, 2015 10:04 AM EDT

Recent Articles from TheStreet

INVESTING

THMA

Pear Therapeutics received its second breakthrough device designation from the Food and Drug Administration for its reSET-A product candidate that is designed for the treatment of alcohol substance use disorder.

INVESTING

TSLA

SpaceX CEO Elon Musk tweets Saturday that the company has started construction on an orbital launch pad at the Kennedy Space Center in Florida for missions to the Moon and Mars.

CANNABIS

PLNHF

The company solidifies its hold on Nevada while launching its California Superstore and planning a U.S. stock listing as well as moves into Chicago and Florida.

INVESTING

Based on Cyber Mondays sales, robot vacuums are on a lot of holiday gift lists this year, with sales of the home appliances up 2,250% from last year.

Tech Rally Sends Hang Seng To Best Gain This Month As Traders Weigh Covid-19 Fallout In China

INVESTING

In the current state of the world, investors are ignoring two key truths, Jim Collins says.

JIM CRAMER

DOCU COUP TOL

Valuations for many stocks are high, says Jim Cramer. That means investors should be on the lookout for potential shocks and new buying opportunities.

INVESTING

AAPL

James 'Rev Shark" Deporre says the disconnect between mega cap stocks holding up the market indexes and struggling shares of many other companies is only getting worse.